ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study

Miyoshi, Jinsei; Zhu, Zhongxu; Luo, Aiping; Toden, Shusuke; Zhou, Xuantong; Izumi, Daisuke; Kanda, Mitsuro; Takayama, Tetsuji; Parker, Iqbal M.; Wang, Minjie; Gao, Feng; Zaidi, Ali H.; Baba, Hideo; Kodera, Yasuhiro; Cui, Yongping; Wang, Xin*; Liu, Zhihua*; Goel, Ajay*北京大学; 中国医学科学院; 中山大学; 中国医学科学院北京协和医院; 6
Molecular Cancer2022-2-11DOI: 10.1186/s12943-022-01507-x
26被引30阅读
引用收藏
分享

摘要

Background Currently, there is no clinically relevant non-invasive biomarker for early detection of esophageal squamous cell carcinoma (ESCC). Herein, we established and evaluated a circulating microRNA (miRNA)-based signature for the early detection of ESCC using a systematic genome-wide miRNA expression profiling analysis. Methods We performed miRNA candidate discovery using three ESCC tissue miRNA datasets (n = 108, 238, and 216) and the candidate miRNAs were confirmed in tissue specimens (n = 64) by qRT-PCR. Using a serum training cohort (n = 408), we conducted multivariate logistic regression analysis to develop an ESCC circulating miRNA signature and the signature was subsequently validated in two independent retrospective and two prospective cohorts. Results We identified eighteen initial miRNA candidates from three miRNA expression datasets (n = 108, 238, and 216) and subsequently validated their expression in ESCC tissues. We thereafter confirmed the overexpression of 8 miRNAs (miR-103, miR-106b, miR-151, miR-17, miR-181a, miR-21, miR-25, and miR-93) in serum specimens. Using a serum training cohort, we developed a circulating miRNA signature (AUC:0.83 [95%CI:0.79-0.87]) and the diagnostic performance of the miRNA signature was confirmed in two independent validation cohorts (n = 126, AUC:0.80 [95%CI:0.69-0.91]; and n = 165, AUC:0.89 [95%CI:0.83-0.94]). Finally, we demonstrated the diagnostic performance of the 8-miRNA signature in two prospective cohorts (n = 185, AUC:0.92, [95%CI:0.87-0.96]); and (n = 188, AUC:0.93, [95%CI:0.88-0.97]). Importantly, the 8-miRNA signature was superior to current clinical serological markers in discriminating early stage ESCC patients from healthy controls (p < 0.001). Conclusions We have developed a novel and robust circulating miRNA-based signature for early detection of ESCC, which was successfully validated in multiple retrospective and prospective multinational, multicenter cohorts.

学科与关键词

关键词
CancerLiquid biopsyBiomarkerEsophageal squamous cell carcinomamicroRNA
相关
加载中…
  • Identification of diagnostic markers and lipid dysregulation in oesophageal squamous cell carcinoma through lipidomic analysis and machine learning
    Yuan, Yuyao; Zhao, Zitong; Xue, Liyan; Wang, Guangxi; Song, Huajie; Pang, Ruifang; Zhou, Juntuo; Luo, Jianyuan; Song, Yongmei*; Yin, Yuxin*British Journal of Cancer, 2021, 125(3): 351-357.被引 13
  • Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
    Rai, Vikrant; Abdo, Joe; Agrawal, Devendra K.*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24(4): 3316.被引 16
  • A multi-platform metabolomics reveals possible biomarkers for the early-stage esophageal squamous cell carcinoma
    Zhao, Jinhui; Zhao, Xinshu; Yu, Jiaying; Gao, Siqi; Zhang, Mingjia; Yang, Tongshu; Liu, Liyan*Analytica Chimica Acta, 2022, 1220: 340038.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Cancer
发表日期
2022-02-11
卷期
第 21 卷, 第 1 期
页码
44
DOI
10.1186/s12943-022-01507-x
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Cancer Institute, National Institutes of Health [CA72851, CA181572, CA184792, CA187956, CA202797]; Cancer Prevention Research Institute of Texas [RP140784]; Sammons Cancer Center; Baylor Scott & White Research Institute, Dallas, TX, USA; Research Grants Council of the Hong Kong Special Administrative Region, China [11103718, 11103619, 11103921, R4017-18, C4041-17GF, AoE/M-401/20]; Guangdong Basic and Applied Basic Research Foundation [2019B030302012]; National Natural Science Foundation of China [81802384]; CMAS Initiative for Innovative Medicine [2021-1-I2M-018]; National Key R&D Program of China [2021YFC2501000]; Baylor Foundation

作者

  • M

    Miyoshi, Jinsei (第一作者)

  • Z

    Zhu, Zhongxu

    chinese univ hong kong

查看全部 18 位作者收起作者
  • L

    Luo, Aiping

    chinese acad med sci · peking union med coll

  • T

    Toden, Shusuke

  • Z

    Zhou, Xuantong

    chinese acad med sci · peking union med coll

  • I

    Izumi, Daisuke

  • K

    Kanda, Mitsuro

  • T

    Takayama, Tetsuji

  • P

    Parker, Iqbal M.

  • W

    Wang, Minjie

    chinese acad med sci · peking union med coll

  • G

    Gao, Feng

    6 · sun yat sen univ

  • Z

    Zaidi, Ali H.

  • B

    Baba, Hideo

  • K

    Kodera, Yasuhiro

  • C

    Cui, Yongping

    hong kong univ sci & technol · peking univ

  • W

    Wang, Xin (通讯)

    chinese univ hong kong

  • L

    Liu, Zhihua (通讯)

    chinese acad med sci · peking union med coll

  • G

    Goel, Ajay (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417